SMA community rallies nationwide to demand access to Spinraza treatment

Yesterday, we stood demanding the right for the SMA community to access the only treatment, Spinraza, for this devastating condition that currently holds the title of the biggest genetic killer of children under 2.

It has been a long time coming to hear there is something that can stop SMA in its tracks. The fight for treatment has been happening for many years with hundreds of children, adults and even families who have passed since and are now not here to witness this day that a drug has been created to save lives and better them. Like us, I am sure their hearts would be broken that we are not allowed to access it even though this drug has been approved in 22 European countries and 35 worldwide.

We stood united. Those that have lost and those that are here waiting. It is our time, we have waited long enough and we will not wait any longer. We refuse to watch those we love waste away in front of us, to the point it kills them. Enough is enough.

TreatSMA is the voice of the People. Treat SMA, Treat it for All, and Treat it now.


London

Over 100 people protested outside the Department of Health in London. Later, we marched by the Houses of Parliament and assembled again in front of the former headquarters of the Department of Health where the Health Secretary still has his offices.

We have handed in a letter requesting a meeting with the Health Secretary.

The London protest was covered by BBC South East:


Manchester

In spite of rainy weather, over 130 people gathered outside the NICE office in Manchester:

BBC North West covered the Manchester protest:


No. 10, Downing Street

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more